Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860295 | 0.78 | HIF1A (0.36) | PTPN1PDE4DHIF1AALOX5HTR2C | |
| SCHEMBL29785076 | 0.74 | ALOX5 (0.50) | DYRK1APTPN1MGAMPDE4DHIF1A | |
| SCHEMBL19436272 | 0.74 | ALOX5 (0.50) | DYRK1APTPN1MGAMPDE4DHIF1A | |
| SCHEMBL7299153 | 0.72 | TSHR (0.32) | TRPA1TSHR | |
| SCHEMBL4234524 | 0.70 | PTPN1 (0.53) | DYRK1APTPN1MGAMPDE4DHIF1A | |
| SCHEMBL2965853 | 0.69 | HSD17B10 (0.35) | PTPN1PDE4DALOX5IDO1TSHR | |
| SCHEMBL16011620 | 0.68 | HIF1A (0.45) | PTPN1MGAMPDE4DHIF1ABCHE | |
| SCHEMBL4046829 | 0.67 | TRPA1 (0.34) | TRPA1TSHR | |
| SCHEMBL23124246 | 0.67 | KDM1A (0.43) | TSHR | |
| SCHEMBL2013649 | 0.66 | PTPN1 (0.39) | PTPN1PDE4DHIF1AALOX5BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| CN-101305005-A | Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | CN | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | DYRK1A 4255/4885PTPN1 2000/4885MGAM 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.